Results 131 to 140 of about 3,264,242 (368)

Cost-Offsets of New Medications for Treatment of Schizophrenia [PDF]

open access: yes
Broad claims are frequently made that new medications will offset all or part of their costs by reducing other areas of Medicaid spending. In this paper we examine the net impact on spending for new drugs used to treat schizophrenia.
Richard G. Frank   +2 more
core  

Sex Differences in Aripiprazole Sensitization from Adolescence to Adulthood [PDF]

open access: yes, 2018
The present study investigated the potential sex differences in repeated aripiprazole (ARI) treatment-induced behavioral sensitization from adolescence to adulthood, and to determine whether ARI sensitization can be transferred to olanzapine (OLZ) and/or
Chow, Shinnyi   +4 more
core   +1 more source

Clozapine as add-on medication in the maintenance treatment of bipolar and schizoaffective disorders - A case series [PDF]

open access: yes, 2002
Atypical neuroleptics are increasingly used in the treatment of bipolar and schizoaffective disorders. Currently, numerous controlled short-term studies are available for clozapine, olanzapine, risperidone or quetiapine, but long-term data are still ...
Amann, B.   +5 more
core   +1 more source

Safety and Effect of 12‐Month Ecopipam Treatment in Pediatric Patients with Tourette Syndrome

open access: yesMovement Disorders Clinical Practice, EarlyView.
Abstract Background Tourette syndrome (TS) is a chronic neurodevelopmental tic disorder with a considerable quality of life (QOL) burden. Objectives The goal was to determine the long‐term safety, tolerability, and clinical effects of ecopipam, a first‐in‐class dopamine D1 receptor antagonist, for TS.
Donald L. Gilbert   +7 more
wiley   +1 more source

Prevalence of High Blood Pressure and its Relationship with Body Weight Factors among Inpatients with Schizophrenia in Taiwan

open access: yesAsian Nursing Research, 2012
Purpose: The objective of this study was to document the prevalence of high blood pressure (BP) and to explore its relationship with weight among inpatients with schizophrenia.
Yu-Li Lan, PhD, Tzy-Ling Chen, PhD
doaj   +1 more source

Patient and Healthcare Professional Preferences for Characteristics of Long-Acting Injectable Antipsychotic Agents for the Treatment of Schizophrenia. [PDF]

open access: yesAdv Ther, 2023
Robinson DG   +7 more
europepmc   +1 more source

Correction: Clozapine, a Novel Antipsychotic Agent [PDF]

open access: bronze, 1994
Olga Delgado Sánchez   +1 more
openalex   +1 more source

Tics and Parkinson's Disease: Clinical and Pathophysiological Insights from a Rare Syndromic Association

open access: yesMovement Disorders Clinical Practice, EarlyView.
Abstract Background The coexistence of tics with Parkinson's disease (PD) is rare, as they often emerge at different ages, follow different trajectories and involve contrasting pathophysiological mechanisms related to dopamine availability and function in the brain. Cases We present 10 individuals with primary tic disorders who later developed PD.
Tarig Abkur   +11 more
wiley   +1 more source

Risk of Drug-induced Movement Disorders with Newer Antipsychotic Agents. [PDF]

open access: yesTremor Other Hyperkinet Mov (N Y), 2022
Kannarkat GT, Caroff SN, Morley JF.
europepmc   +1 more source

The agonist activities of the putative antipsychotic agents, L‐745,870 and U‐101958 in HEK293 cells expressing the human dopamine D4.4 receptor [PDF]

open access: green, 1998
Lucien Gazi   +9 more
openalex   +1 more source

Home - About - Disclaimer - Privacy